| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_658df3b9d24eb5224b37aaf605741db6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-475 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate |
2011-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2016-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bcbaf0d8ff1a66ae5d8442e841847a70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5344971ecf06af90a4890dae578e3f48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82cbffd9288fd2f4e30c092ec6eaf87c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c50b49ad6cf2c01311bc864386babb05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5a23fa137d592d837b10adbd910e1a6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a82e56aca82dfa79616d58e1d5b3335a |
| publicationDate |
2016-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2011268327-B2 |
| titleOfInvention |
Single chain insulin agonists exhibiting high activity at the insulin receptor |
| abstract |
Single chain insulin analogs are provided having high potency and specificity for the insulin receptor. As disclosed herein optimally sized linking moieties can be used to link human insulin A and B chains, or analogs or derivatives thereof, wherein the carboxy terminus of the B25 amino acid of the B chain is linked to the amino terminus of the Al amino acid of the A chain via the intervening linking moiety. In on embodiment the linking moiety comprises a polyethylene glycol of 6-16 monomer units and in an alternative embodiment the linking moiety comprises a non-native amino acid sequence derived form the IGF-1 C-peptide and comprising at least 8 amino acids and no more than 12 amino acid in length. Also disclosed are prodrug and conjugate derivatives of the single chain insulin analogs. |
| priorityDate |
2010-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |